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Table 1a
Baseline Characteristics
Patient Characteristic Bu-Cy Cy-Bu P Value
Total patients 18 22
Sex .424
Male 15 16
Female 3 6
Age
Median (range) 17 (1-50) 16 (1-48) .85
Mean 21.83 22.81 .899
<14 yr 7 7
14-45 yr 10 13
>45 yr 1 2
Underlying disease .415
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dividuals in the United States and causes considerable
morbidity and mortality. Hematopoietic stem cell trans-
plantation (HSCT) is the only cure for patients with SCD.
Multiple studies show matched sibling transplants after
myeloablative (MAB) conditioning have acceptable results,
but with potential long-term complications, like endocrine
and fertility issues. Only 14% of SCD patients will have
acceptable sibling donors, and results have been less
promising with higher rates of transplant related mortality
(TRM) using alternative donors after MAB conditioning.
Historically, only pediatric patients were considered can-
didates for HSCT, but a recent study demonstrated that
young adult SCD patients may be able to tolerate a RIC
HSCT with minimal complications. In an attempt to
minimize the risk of TRM while still maximizing the
available donors, this study examines the use of a RIC
regimen for either matched sibling or alternative donor
HSCT in SCD patients ages 2-30.
Methods: Patients were deemed eligible for matched sibling
HSCT if they had SCD, and for alternative donor HSCT if they
had SCDwith severe features with a 9-10/10 unrelated donor
or 5-6/6 UCB in the donor registry. The conditioning regimen
consisted of Alemtuzumab, Fludarabine, and Melphalan.
Post-HCST, donor chimerism and hemoglobin S (HbS) per-
centages were followed closely, and there was strict moni-
toring for post-HSCT complications, including graft rejection,
graft vs. host disease (GVHD), infectious complications, and
other post-HSCT issues.
Results: 11 patients (8 related donors, 3 unrelated donors)
with median age of 8.1 years (range: 2.3-23 years) were
enrolled. For related HSCT, the probabilities of primary
neutrophil & platelet engraftment, grade II-IV acute GVHD,
chronic GVHD, and graft rejectionwere 100%, 27%, 12.5%, and
0%, respectively. Donor chimerisms ranged from 96-100%
with HbS% between 0-43%, with median follow-up of 19
months (range: 3-24months). Probability of 1-yr DFS and OS
were 100% & 100%. For alternative donor HSCT, the proba-
bilities of primary neutrophil & platelet engraftment, grade
II-IV GVHD, chronic GVHD, and graft rejection were 100%,
33%, 33%, and 33%, respectively. Donor chimerisms ranged
from 0-100%with HbS% between 0-18%, with median follow-
up of 8 months (range: 2-25 months). Probability of 1-yr DFS
and OS were 33% & 66%.
Conclusions: Our results show that this RIC regimen fol-
lowed by matched sibling HSCT is well tolerated, but the
results were discouraging for alternative donor HSCT.
Because of this, we are currently developing a protocol using
post-transplant cyclophosphamide in alternative donor
HSCT for SCD.AML 14 12
ALL 3 4
CML 1 3
MDS 0 2
Primary myeloﬁbrosis 0 1
Stage of disease .984
Early 3 4
Intermediate 8 10
Late 7 8
Pre-transplant remission status .482
CR 11 11
Not in CR 7 11
Performance status (ECOG) .314
0 4 3
1 9 16
HSCT comorbidity index .341
0 14 15
1 1 5
2 2 2
3 1 0384
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Most adult ALL protocols include consolidation chemotherapy,
yet whether the consolidation is beneﬁcial in patients under-
going alloHCT in ﬁrst complete remission (CR1) remains un-
certain. We therefore studied the impact of consolidation
chemotherapy on transplant outcomes of 75 consecutive ALLpatientswho received alloHCT in CR1 between 2004 and 2013.
Patientswho received at least 1 cycle of consolidation (n¼51; 1
cycle, n¼25;2 cycles, n¼26)were compared to thosewithout
consolidation (n¼24) chemotherapy prior to alloHCT. The
median age of entire cohort was 42 years (range, 19-67) and
59% were males. Half had Ph+ ALL and 16% had CNS leukemia.
Patients received median of 2 cycles of induction chemo-
therapy (range, 1-5), and the median time from diagnosis to
CR1 was 1.6 months (range, 1.1-2.9). Among 54 patients
evaluable for minimal residual disease (MRD), 42 were MRD
negative prior to alloHCT. Most patients received myeloa-
blative conditioning (67%) and umbilical cord blood (UCB, 63%)
alloHCT. Patients in 1 consolidation group were more often
transplanted after 2008 (75% vs. 31%, p<0.01) as compared to
no consolidation group, however other patient, disease and
transplant characteristics were similar in both groups. At a
median follow up of 4 years (range,1-8), patients treated with
1 cycles of consolidation versus no consolidation had similar
1-year non-relapse mortality (24% vs. 29%, p¼0.23), 2-year
leukemia relapse (23% vs. 25%, p¼0.44), leukemia-free survival
(48%vs. 36%,p¼0.18) andoverall survival (61%vs. 45%,p¼0.15),
respectively. Cumulative incidence of relapse was lower in
MRD negative patients (17% vs 50% MRD+, p¼0.03) and UCB
recipients (15%vs 37% related donor, p¼0.02). Our data suggest
that ALL patients with available donor undergoing alloHCT in
CR1may not beneﬁt from further pre-transplant consolidation
chemotherapy.385
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